Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Takamichi YokoeSasagu KurozumiKazuki NozawaYukinori OzakiTetsuyo MaedaShu YazakiMai OnishiAkihiro FujimotoSayuka NakayamaYuko TsuboguchiTsutomu IwasaHitomi SakaiMisato OgataMitsuo TeradaMeiko NishimuraTakuma OnoeJun MasudaMichiko KurikawaHirotsugu IsakaKanako HagioAkihiko ShimomuraYuta OkumuraManabu FutamuraMototsugu ShimokawaToshimi TakanoPublished in: Breast cancer (Tokyo, Japan) (2021)
The benefits of treatments after T-DM1 are limited. Further investigation of new treatment strategies beyond T-DM1 is awaited for HER2-positive metastatic breast cancer patients.